Drug Trial Radar · NCT05267626
Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
Last checked: Nov 19, 2026Latest source record: Sep 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
159
Planned (sponsor's estimate)
Start
Apr 4, 2022
Primary completion
Feb 28, 2027
Study completion Feb 28, 2027
Sponsor
- Lead sponsor
- Aulos Bioscience, Inc.Industry
- Sponsor type
- Industry
- First posted
- Mar 4, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a first in human, open-label, multi-center Phase 1 / 2 study to evaluate the safety, tolerability, and initial efficacy of AU-007, also known as imneskibart, in patients with advanced solid tumors. AU-007 will be administered either as a monotherapy, or in combination with a single loading dose of aldesleukin, or with both AU-007 and aldesleukin given every 2 weeks (Q2w). Once the recommended phase 2 dose (RP2D) of AU-007 plus aldesleukin was determined, (AU-007 Q2w plus a single loading dose of aldesleukin), AU-007 plus aldesleukin is also being administered with avelumab or nivolumab.
Conditions
- Advanced Solid Tumor
- Metastatic Cancer
- Cutaneous Melanoma
- Non-Small Cell Lung Cancer
Interventions
AU-007Drug
Monoclonal Antibody Targeting IL-2
AldesleukinDrug
IL-2
AvelumabDrug
Monoclonal Antibody Targeting PD-L1
NivolumabDrug
Monoclonal Antibody Targeting PD-1
Primary outcomes
What the sponsor says the trial is designed to measure.
- Evaluate the safety and tolerability of AU-007Time frame: Day 1 thru end of treatment (EOT) visit (28 days after last dose)
- Establish the maximum tolerated dose (MTD) and/or RP2DTime frame: Day 1 thru EOT visit (28 days after last dose)
Locations
17 sites in 2 countries. Site status is shown where the registry gives one.
Sylvester Comprehensive Cancer Center - Miami
Miami, Florida · Recruiting
START Midwest
Grand Rapids, Michigan · Recruiting
Minnesota Oncology and Hematology PA
Minneapolis, Minnesota · Recruiting
Washington University
St Louis, Missouri · Recruiting
Carolina Biooncology Institute
Huntersville, North Carolina · Recruiting
Sarah Cannon Research Institute
Nashville, Tennessee · Recruiting
Texas Oncology (Balcones) - SCRI
Austin, Texas · Recruiting
MD Anderson Cancer Center
Houston, Texas · Recruiting
START South Texas Accelerated Research Therapeutics
San Antonio, Texas · Recruiting
University of Utah - Huntsman Cancer Institute
Salt Lake City, Utah · Recruiting
Southside Cancer Care Centre
Miranda, New South Wales, Australia · Recruiting
Southern Oncology Clinical Research Unit
Bedford Park, South Australia, Australia · Recruiting
Monash Health
Clayton, Victoria, Australia · Recruiting
Peninsula & South Eastern Haematology and Oncology Group
Frankston, Victoria, Australia · Recruiting
Austin Health
Heidelberg, Victoria, Australia · Recruiting
The Alfred Hospital
Melbourne, Victoria, Australia · Recruiting
Sunshine Hospital
Saint Albans, Victoria, Australia · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.